Mesothelioma – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of mesothelioma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of mesothelioma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s mesothelioma forecast will answer the following questions:
- How many in each country in the major mature pharmaceutical markets have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of mesothelioma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods
In total, Clarivate Epidemiology forecasts one mesothelioma patient population, as follows:
- Diagnosed incident cases
Note: Coverage may vary by country.
